Healthcare Industry News: ATRILAZE
News Release - September 11, 2007
Michael A. Brodeur to Join MedicalCV, Inc. as Chief Financial Officer
MINNEAPOLIS--(HSMN NewsFeed)--MedicalCV, Inc. (OTCBB:MCVI ), www.medcvinc.com, announced today that Michael A. Brodeur has agreed to join its executive team as Vice President, Finance and Chief Financial Officer, effective September 17, 2007.Marc P. Flores, MedicalCV's President and Chief Executive Officer, stated, "Michael's extensive finance experience with medical therapeutics and leading-edge medical technologies will be a welcome and immediate asset to MedicalCV." Flores added, "We look forward to his insights as we prepare for the full commercial launch of our SOLAR(TM) Surgical Ablation System and support continued use of the ATRILAZE(TM) Surgical Ablation System in open, endoscopic, and robotic-assisted procedures."
"I am excited to join this truly dynamic team of individuals as it continues to expand its presence in the developing surgical ablation market," stated Mr. Brodeur. "I look forward to helping MedicalCV become the premier player in the atrial fibrillation space."
Mr. Brodeur has over 25 years of senior financial leadership in healthcare, medical device, biotechnology and clinical laboratory industries. Mr. Brodeur has worked with national CFO services firms serving emerging, middle-market and multinational companies such as Tatum CFO Partners, LLP. Mr. Brodeur served as CFO of Molecular Diagnostics, Inc. and Aastrom Biosciences, Inc., publicly traded medical device companies. Mr. Brodeur has also served as CFO of McKesson Medication Management, Inc. and Meris Laboratories, Inc. and held senior financial leadership positions with EPS Solutions Corporation and WellPoint Health Networks Inc. Mr. Brodeur is a certified public accountant who began his career at Ernst & Young.
About MedicalCV, Inc.
MedicalCV, Inc. is a medical device company that develops, manufactures and sells innovative, laser-based surgical ablation systems to create precise, clinically relevant lesions, or scars, in soft tissue and in cardiac tissue. The Company's core products are the SOLAR(TM) and ATRILAZE(TM) Surgical Ablation Systems for use in soft and cardiac tissue ablation procedures, respectively. The ATRILAZE(TM) System has been utilized in concomitant open-heart and, by some cardiothoracic surgeons, in minimally invasive cardiac surgery procedures. The SOLAR(TM) System has been used in concomitant ablation procedures on both stopped and beating hearts. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MCVI".
This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this release refer to expectations regarding the commercialization of the company's ATRILAZE(TM) and SOLAR(TM) Surgical Ablation Systems. These forward-looking statements reflect management's expectations and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: the Company's ability to obtain financing required to continue operations; the ability to gather acceptable clinical data in a timely manner to support additional regulatory clearances; the ability of the Company's suppliers to provide it with suitable clinical product; competing technological and market developments; physician acceptance of the Company's products; dependence upon reimbursements and third party payors; and the strength of the market for ablation products. For more detailed information about these risks and uncertainties, please review the Cautionary Statement set forth in the Company's Annual Report on Form 10-KSB, as filed with the Securities and Exchange Commission on July 25, 2007.
These events and uncertainties are difficult or impossible to predict accurately and many are beyond the Company's control. The Company assumes no obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect events or uncertainties after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
For further information on MedicalCV, Inc., please visit www.medcvinc.com.
Source: MedicalCV
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
